The role of secukinumab in the treatment of ankylosing spondylitis

Rashmi Shah, Lisa Perry, Atul Deodhar

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Ankylosing spondylitis is a chronic inflammatory disorder involving the sacroiliac joint, spine and less frequently the peripheral joints. Nonsteroidal anti-inflammatory drugs and TNF-α inhibitors are utilized to reduce signs and symptoms. Whether these agents slow disease progression, is still debatable. Secukinumab is a fully human monoclonal antibody against IL-17 that has been studied in patients with ankylosing spondylitis with promising results. It has demonstrated improvement in signs, symptoms, patient reported outcomes and functional status and has been well tolerated. The clinical improvement is also mirrored in the improvement in sacroiliac joint magnetic resonance imaging scans.

Original languageEnglish (US)
Pages (from-to)1241-1247
Number of pages7
JournalImmunotherapy
Volume7
Issue number12
DOIs
StatePublished - Dec 2015

    Fingerprint

Keywords

  • ankylosing spondylitis
  • axial spondyloarthritis
  • interleukin-17
  • interleukin-17 inhibitors
  • secukinumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this